Equities Analysts Offer Predictions for Omnicell Q2 Earnings

Omnicell, Inc. (NASDAQ:OMCL - Free Report) - Investment analysts at Zacks Research lowered their Q2 2025 earnings per share estimates for shares of Omnicell in a note issued to investors on Wednesday, June 18th. Zacks Research analyst R. Department now forecasts that the company will earn $0.10 per share for the quarter, down from their previous forecast of $0.12. The consensus estimate for Omnicell's current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell's Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.16 EPS, FY2025 earnings at $0.28 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.22 EPS, FY2026 earnings at $0.44 EPS, Q1 2027 earnings at ($0.03) EPS and FY2027 earnings at $0.88 EPS.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.10. Omnicell had a return on equity of 4.60% and a net margin of 1.87%. The business had revenue of $269.67 million during the quarter, compared to analysts' expectations of $260.18 million. During the same period in the prior year, the business earned $0.03 EPS. The business's revenue for the quarter was up 9.5% compared to the same quarter last year.

Other equities research analysts have also recently issued reports about the company. Benchmark decreased their price target on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Bank of America increased their price target on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 23rd. Piper Sandler restated an "overweight" rating on shares of Omnicell in a research note on Friday, May 23rd. Wells Fargo & Company restated an "overweight" rating and issued a $37.00 price objective (up from $35.00) on shares of Omnicell in a research note on Friday, May 23rd. Finally, JPMorgan Chase & Co. reduced their price objective on Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday, March 20th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Omnicell currently has a consensus rating of "Moderate Buy" and a consensus price target of $44.83.

Omnicell Trading Down 0.8%

Shares of NASDAQ OMCL opened at $28.03 on Monday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.38 and a quick ratio of 1.23. The stock has a market capitalization of $1.31 billion, a P/E ratio of 60.94 and a beta of 0.78. Omnicell has a 1-year low of $22.66 and a 1-year high of $55.75. The business has a fifty day moving average price of $29.45 and a 200 day moving average price of $36.29.

Institutional Trading of Omnicell

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Omnicell by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company's stock valued at $247,628,000 after purchasing an additional 28,573 shares during the period. Victory Capital Management Inc. grew its holdings in Omnicell by 10.1% in the first quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company's stock valued at $58,745,000 after purchasing an additional 154,038 shares during the period. Dimensional Fund Advisors LP grew its holdings in Omnicell by 31.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock valued at $73,127,000 after purchasing an additional 394,820 shares during the period. Lazard Asset Management LLC grew its holdings in Omnicell by 81.6% in the fourth quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock valued at $73,093,000 after purchasing an additional 737,536 shares during the period. Finally, ArrowMark Colorado Holdings LLC grew its holdings in Omnicell by 4.9% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 1,196,990 shares of the company's stock valued at $53,290,000 after purchasing an additional 56,117 shares during the period. 97.70% of the stock is owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.